1. Home
  2. AZTR vs SNOA Comparison

AZTR vs SNOA Comparison

Compare AZTR & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.21

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$1.15

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AZTR
SNOA
Founded
2014
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
4.0M
IPO Year
2023
2006

Fundamental Metrics

Financial Performance
Metric
AZTR
SNOA
Price
$0.21
$1.15
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
9.9M
88.5K
Earning Date
05-08-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
5.06
32.26
EPS
N/A
N/A
Revenue
N/A
$19,529,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.68
52 Week Low
$0.10
$0.85
52 Week High
$1.40
$6.92

Technical Indicators

Market Signals
Indicator
AZTR
SNOA
Relative Strength Index (RSI) 46.26 46.13
Support Level $0.19 $1.00
Resistance Level $0.25 $1.25
Average True Range (ATR) 0.03 0.08
MACD -0.00 0.02
Stochastic Oscillator 17.88 52.17

Price Performance

Historical Comparison
AZTR
SNOA

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: